Patents by Inventor Mona Lindstrom

Mona Lindstrom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6706710
    Abstract: This invention relates to a novel form of a scrotonin h5-HT1B-receptor antagonist, namely a novel form of a salt of (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,2,4-tetrahydro-2-naphtyl]-4-morpholinobenzamide referred to as (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphtyl]-4-morpholinobenzamide monohydrobromide Form A. The invention also relates to processes for preparation of said of Form A, which form has a potential use after suitable pharmaceutical formulation in medical treatment, preferably in CNS disorders, over active bladder or vasospam, or growth control of tumors.
    Type: Grant
    Filed: January 17, 2003
    Date of Patent: March 16, 2004
    Assignee: AstraZeneca AB
    Inventors: Per-Olov Bergström, Martin Hedberg, Mona Lindström, Erica Ståhle
  • Publication number: 20030166653
    Abstract: This invention relates to a novel form of a serotonin h5-HT1B-receptor antagonist, namely a novel form of a salt of (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphtyl]-4-morpholinobenzamide referred to as (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphtyl]-4-morpholinobenzamide monohydrobromide Form A. The invention also relates to processes for preparation of said of Form A, which form has a potential use after suitable pharmaceutical formulation in medical treatment, preferably in CNS disorders, over active bladder or vasospam, or growth control of tumors.
    Type: Application
    Filed: January 17, 2003
    Publication date: September 4, 2003
    Inventors: Per-Olov Bergstrom, Martin Hedberg, Mona Lindstrom, Erica Stahle